🔗 Share this article

Given that America proceeds with sweeping revisions to its vaccine guidelines, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by expressing skepticism about Covid shots in the pandemic and has focused upon alleged deaths following Covid immunization in her short time at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Vaccine Schedule

Health officials had intended to reveal sweeping changes to the childhood vaccine schedule earlier this month, bringing the US with Denmark’s vaccine program, sources say – a substantial departure that would put the US out of step with much of the international standard with little proof for benefit. This reveal has been delayed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to present at the gathering. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth person to head the office this year.

Consolidating Power at the FDA

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending specific childhood immunization guidelines in the US so as to align more like Denmark, a nation with comprehensive healthcare and a citizenry approximately the size of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on immunizations – traditionally the purview of Dr. Prasad, chief of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Background

Dr. Høeg has no obvious experience in medication creation, approval processes or administrative roles, which has been typical for former leaders of the biologics center. She has worked at the FDA as a key advisor to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a large organization. She is not an expert in drug approvals.”

Former directors of the center would “understand legal statutes and the science of medication creation”, noted Janet Woodcock. “Clearly, she doesn’t have the type of experience that former directors who ran CBER have had.”

CDER has an enormous portfolio at the agency, Woodcock emphasized.

“Everybody just focuses on the innovative therapies, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and so forth, and every single one must be supervised,” Dr. Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial administrative component to the position, which oversees in excess of 5,000 personnel. “It is a enormous administrative position, if you perform it correctly,” the former official said.

Response and Contentious Initiatives

Regarding questions about Dr. Høeg's fitness for the role and whether this assignment indicates increased cooperation among FDA leaders on immunizations, a representative responded that the “inquiries are based on inaccurate assumptions”.

“This background is consistent with the responsibilities of her role,” the spokesperson explained, citing the period Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a controversial one-day medication authorization process that allegedly worried her predecessors. “By what process are these drugs being selected for this voucher program? Who makes the choices?” Dr. Howard asked. “There is a lot of secrecy happening at the agency right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards laxer rules of pharmaceuticals, aside from immunizations.”

Established Track Record on Vaccines

With immunizations, Høeg has a more established, if troubling, track record, some experts observe. She released a analysis using unconfirmed crowd-sourced reports to determine the rate of myocarditis after Covid immunization. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the new federal leadership featured changing regulations for recently developed shots and halting “unnecessary” vaccines, she remarked post-election on a audio program. At the FDA, Dr. Høeg has allegedly suggested preventing young men from receiving COVID-19 vaccines.

“She’s an thorough ideologue who begins with her beliefs and works backwards to accommodate the data in a highly disingenuous, fraudulent manner,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|